Eagle Pharmaceuticals Inc. (EGRX) 34.00 $EGRX 5 Stocks

Eagle Pharmaceuticals Inc. (EGRX) 34.00 $EGRX

5 Stocks With Jaw-Dropping Growth Potential
George Budwell, The Motley Fool - Motley Fool - Sat Feb 28, 8:04AM CST
With the U.S. stock market hitting record highs of late and red hot sectors like health care sporting some jaw-dropping premiums, it's getting harder and harder to find stocks with compelling valuations. That being said, there are still a handful of...
VRX: 197.48 (-3.77), FLML: 15.65 (+0.35), PTX: 10.73 (-0.17), AZN: 68.90 (-0.11), TEVA: 57.02 (+0.53), GSK: 47.42 (-0.42), EGRX: 34.00 (-0.26), SNY: 48.86 (-0.01), ARDX: 15.74 (-0.27), IG: 11.52 (+0.32)

Nasdaq stocks posting largest volume increases
AP - Fri Feb 20, 5:00PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 26.30 (+0.80), CLSN: 2.89 (-0.05), SBBX: 10.48 (-0.07), NDLS: 18.23 (-0.63), HOTR: 2.20 (+0.12), EGRX: 34.00 (-0.26), ONVI: 4.66 (-0.03), JAXB: 10.50 (-0.25), BWFG: 19.40 (-0.28), FBSS: 17.15 (+0.15)

Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 20, 5:00PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RESN: 10.40 (-5.07), UIHC: 24.41 (-0.29), UEIC: 56.51 (+0.89), ALDX: 10.20 (-0.07), AXDX: 20.00 (-0.24), ANGI: 6.74 (+0.35), VNDA: 10.76 (-0.28), FUEL: 9.77 (-0.19), NDLS: 18.23 (-0.63), NMIH: 7.30 (-0.03), EGRX: 34.00 (-0.26)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 11:45AM CST

BNSO: 1.52 (+0.09), BONE: 3.59 (+0.38), FUEL: 9.77 (-0.19), ASTI: 1.41 (-0.09), AHS: 22.56 (-0.28), AXN: 1.10 (-0.12), EGRX: 34.00 (-0.26), NBG: 1.57 (-0.16), GTT: 15.51 (+0.07), WBAI: 9.23 (-0.87), GENE: 5.83 (-0.71), EGLT: 15.01 (+0.03), SAAS: 11.71 (+0.21), CLRX: 1.35 (-0.06), CAS: 3.22 (-1.81), NDLS: 18.23 (-0.63), TRUE: 19.90 (+0.69), HOTR: 2.20 (+0.12), SZMK: 7.90 (+0.01), BLDR: 6.03 (-0.12)

Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST

GENE: 5.83 (-0.71), HTBX: 6.66 (-0.16), SGNL: 2.70 (-0.21), ROSG: 3.41 (-0.10), TTPH: 39.46 (-2.74), ONCY: 0.73 (-0.04), CLRX: 1.35 (-0.06), MELA: 1.77 (-0.07), AKAO: 11.17 (-0.09), WGBS: 4.98 (+0.40), EGRX: 34.00 (-0.26)

Teva to Commercialize Eagle's Cancer Drug in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 12:20PM CST
Teva (TEVA) signed a deal to commercialize Eagle's bendamustine hydrochloride rapid infusion candidate in the U.S.
IPXL: 40.29 (-0.41), ACT: 291.36 (+1.58), TEVA: 57.02 (+0.53), EGRX: 34.00 (-0.26)

Eagle Pharmaceuticals incurs higher net loss of USD5.5m for three month period ended 31 December 2014
M2 - Wed Feb 18, 6:49AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) disclosed on Tuesday that it recorded a net loss of USD5.5m (USD0.39 per basic and diluted common share) for the transitional three-month period ended 31 December 2014 (the stub period).
EGRX: 34.00 (-0.26)

Eagle Pharmaceuticals reports 4Q loss
Automated Insights - Wed Feb 18, 4:03AM CST
WOODCLIFF LAKE, N.J. (AP) _ Eagle Pharmaceuticals Inc. (EGRX) on Wednesday reported a loss of $5.5 million in its fourth quarter.
EGRX: 34.00 (-0.26)

Eagle Pharmaceuticals beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 3:44PM CST

EGRX: 34.00 (-0.26)

Eagle Pharmaceuticals, Inc. Reports Financial Results for Three Month Period Ended December 31, 2014
Business Wire - Tue Feb 17, 3:02PM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company" (Nasdaq:EGRX) today announced its financial results for the transitional three-month period ended December 31, 2014 (the "stub period" . This stub period resulted from the previously-announced change in Eagle's year end from September 30 to December 31. The company will report financial results of the first quarter of 2015 in May.
EGRX: 34.00 (-0.26)

Why Shares of Eagle Pharmaceuticals Inc. Ripped Higher
George Budwell, The Motley Fool - Motley Fool - Tue Feb 17, 12:31PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What:  Shares of developmental-stage biopharma  Eagle...
TEVA: 57.02 (+0.53), EGRX: 34.00 (-0.26)

Eagle and Teva team up in blood cancer
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:05AM CST

TEVA: 57.02 (+0.53), EGRX: 34.00 (-0.26)

Eagle Pharmaceuticals to Hold Conference Call at 8:30 a.m. EST Today to Discuss Licensing Agreement with Teva to Commercialize Eagle's Rapid Infusion Bendamustine
Business Wire - Tue Feb 17, 6:05AM CST
Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company" (Nasdaq:EGRX), will hold a conference call to discuss its newly-disclosed license agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) for EP-3102, Eagle's bendamustine hydrochloride (HCl) rapid infusion product. Interested parties may access the call as follows:
TEVA: 57.02 (+0.53), EGRX: 34.00 (-0.26)

Teva and Eagle Pharmaceuticals Announce Teva's License to Commercialize Eagle's Bendamustine Rapid Infusion Product
Business Wire - Tue Feb 17, 6:01AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) today announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle's bendamustine hydrochloride (HCl) rapid infusion product for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva.
TEVA: 57.02 (+0.53), EGRX: 34.00 (-0.26)